I have to agree with Cityslicker that "this could be huge" for Apabetalone as long as it works as well in the clinc as it is working in the lab. Hopefully RVX is getting the CoVid trial together ASAP.  If Apabetalone does in fact meet this CoVid promise wrt to heart and lung tissue as well as cytokine storm, that plus BTD could possibly make this drug irresistible to big pharma. I agree Golf, it could be golden IF it works in the clinic. 

CitySlicker from March 3....

"This could be huge. We'll have to wait until the peer review is finished, but if the referees see no flaws, this report from a major research institute seems as good as it gets for a pre-clinical study. A 75% reduction in mortality in such experimental work is astounding. One rarely sees such efficacy.  If apabetalone prevents or controls cytokine storms at the epigenetic level in covid patients, it probably will do also in cytokine storms complicating other clinical conditions, of which there are many!"

https://www.nejm.org/doi/full/10.1056/NEJMra2026131